Clinical trial
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
NCT03953235
Study timeline
Study start (actual)2019-07-18Date precision: day
Registry last updated2023-09-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-Small Cell Lung Cancerunresolved
Colorectal Cancerunresolved
Pancreatic Cancerunresolved
Solid Tumorunresolved
Shared Neoantigen-Positive Solid Tumorsunresolved
Interventions
Sponsors & collaborators
Gritstone bio, Inc.lead sponsor
Bristol-Myers Squibbcollaborator
Mapped research locations
New YorkNew York, United States2HoustonTexas, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1NashvilleTennessee, United States1ColumbusOhio, United States1PhoenixArizona, United States1JacksonvilleFlorida, United States1RochesterMinnesota, United States1FairfaxVirginia, United States1Santa MonicaCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03953235 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.